Study Says FDA Review of GM Salmon “Incomplete”

THIRD WORLD NETWORK BIOSAFETY INFORMATION SERVICE
 
Dear Friends and colleagues,
 
RE: Study Says FDA Review of GM Salmon "Incomplete"
 
A new study by Duke University has joined the chorus of criticism against the process used by the US Food and Drug Administration (FDA) in its review of GM salmon, which if approved, will be the first GM animal for commercial release as food.
 
The study, which is published in the journal Science, said the FDA presents "an incomplete picture" of the risks and benefits of GM salmon. It says the review process has been very limited and argued that a full review is needed that would consider broader definitions of environmental safety and public health as well as a fuller assessment of the potential economic and environmental impacts.
 
The study "Genetically Modified Salmon and Full Impact Assessment", by Martin D. Smith, Frank Asche, Atle G. Guttormsen, Jonathan B. Wiener is published in Science, Vol. 330 No. 6007, November 19 2010 (http://www.sciencemag.org/content/330/6007/1052.short) (Subscription is required for the full text.)
 
With best wishes,
Third World Network
131 Jalan Macalister,
10400 Penang,
Malaysia

————————————————————————————————————

New Study Claims FDA Review of GM Salmon Is Incomplete

Mike Ludwig

t r u t h o u t, 24 November 2010

http://www.truth-out.org/new-study-claims-fda-review-gm-salmon-incomplete65405

The process used by the Food and Drug Administration (FDA) to review genetically modified (GM) salmon presents "an incomplete picture" of the risks and benefits of what could be the first GM animal food approved for human consumption, according to a recent Duke University study.

The FDA found the GM salmon safe to eat in September. A comment period on whether the FDA can require GM salmon to be labeled as GM expired on Monday, putting the agency one step closer to a final decision.

The Duke Study, published in the latest issue of Science magazine, echoes the concerns of anti-GM activists, who argue in public hearings that the FDA has not considered enough data on the potential health and environmental consequences of farming GM salmon.

"Instead of focusing on the safety of a food taken one portion at a time, or whether it was produced through genetic modifications or through classic breeding, a more useful approach would be to evaluate whether society is better off overall with the new product on the market than without it," said Jonathan B. Wiener, one of the study’s co-authors.

Members of Congress have also expressed concern about the review process, and last week, senators from Alaska introduced legislation that would ban GM salmon if the FDA approves the fish.

The FDA is reviewing the salmon, which have extra genes that cause the fish to grow larger and faster, as a "new animal drug."

Duke environmental economics professor Martin Smith said the review process has ignored broad effects that large, fast-growing salmon could have on the environment and society, like how cheaper salmon might lower prices and increase consumption.

"These market impacts could dwarf any small differences in nutritional content," Smith said.

Smith said the review process has only compared the nutritional value of GM salmon to regular salmon and screened for known toxins and allergens.

Smith and his team argue a full review would consider broader definitions of environmental safety and public health. The FDA should also make a fuller assessment of potential economic and environmental impacts, such as the amount of pollution created by salmon farms and the increased harvesting of the wild fish used to feed farmed salmon.

FDA spokesperson Siobhan DeLancey said the FDA did not receive a copy of the Duke study and the review process is still under way.

Smith and his team also argued the FDA should have put more thought into the potential threat GM salmon could pose to native salmon if the fish escaped into the wild.

Last week, watchdog group Food and Water Watch released internal documents from the Department of the Interior to Truthout showing that federal wildlife officials are concerned about the GM salmon proposal and the FDA’s failure to consult the Fish and Wildlife Service about the potential for the salmon to escape and threaten endangered populations in the wild.

"The approval of genetically modified salmon will set an important precedent for other transgenic animals intended for human consumption," Smith said in a statement. "It’s essential that FDA establishes an approval process that assesses the full portfolio of impacts to ensure that such decisions serve society’s best interests."

AquaBounty Technologies, the company that spent a decade developing the GM salmon, has proposed to breed the fish in inland tanks in Canada and then grow them in Panama.

Some activists are concerned that a decision on the salmon is imminent, but DeLancey said the agency is still reviewing comments from the industry and the public.

The FDA also has to decide whether to prepare a Finding of No Significant Impact or an Environmental Impact Statement, a preliminary decision that would be subject to a 30-day comment period.

The impact statement is based on an environmental analysis that Fish and Wildlife Service officials called inadequate, according to documents released to Truthout.

 

Study Says FDA Review of GM Salmon “Incomplete”

New Study Claims FDA Review of GM Salmon Is Incomplete
Mike Ludwig
t r u t h o u t, 24 November 2010
 
The process used by the Food and Drug Administration (FDA) to review genetically modified (GM) salmon presents "an incomplete picture" of the risks and benefits of what could be the first GM animal food approved for human consumption, according to a recent Duke University study.
 
The FDA found the GM salmon safe to eat in September. A comment period on whether the FDA can require GM salmon to be labeled as GM expired on Monday, putting the agency one step closer to a final decision.
 
The Duke Study, published in the latest issue of Science magazine, echoes the concerns of anti-GM activists, who argue in public hearings that the FDA has not considered enough data on the potential health and environmental consequences of farming GM salmon.
 
"Instead of focusing on the safety of a food taken one portion at a time, or whether it was produced through genetic modifications or through classic breeding, a more useful approach would be to evaluate whether society is better off overall with the new product on the market than without it," said Jonathan B. Wiener, one of the study’s co-authors.
 
Members of Congress have also expressed concern about the review process, and last week, senators from Alaska introduced legislation that would ban GM salmon if the FDA approves the fish.
 
The FDA is reviewing the salmon, which have extra genes that cause the fish to grow larger and faster, as a "new animal drug."
 
Duke environmental economics professor Martin Smith said the review process has ignored broad effects that large, fast-growing salmon could have on the environment and society, like how cheaper salmon might lower prices and increase consumption.
 
"These market impacts could dwarf any small differences in nutritional content," Smith said.
 
Smith said the review process has only compared the nutritional value of GM salmon to regular salmon and screened for known toxins and allergens.
 
Smith and his team argue a full review would consider broader definitions of environmental safety and public health. The FDA should also make a fuller assessment of potential economic and environmental impacts, such as the amount of pollution created by salmon farms and the increased harvesting of the wild fish used to feed farmed salmon.
 
FDA spokesperson Siobhan DeLancey said the FDA did not receive a copy of the Duke study and the review process is still under way.
 
Smith and his team also argued the FDA should have put more thought into the potential threat GM salmon could pose to native salmon if the fish escaped into the wild.
 
Last week, watchdog group Food and Water Watch released internal documents from the Department of the Interior to Truthout showing that federal wildlife officials are concerned about the GM salmon proposal and the FDA’s failure to consult the Fish and Wildlife Service about the potential for the salmon to escape and threaten endangered populations in the wild.
 
"The approval of genetically modified salmon will set an important precedent for other transgenic animals intended for human consumption," Smith said in a statement. "It’s essential that FDA establishes an approval process that assesses the full portfolio of impacts to ensure that such decisions serve society’s best interests."
 
AquaBounty Technologies, the company that spent a decade developing the GM salmon, has proposed to breed the fish in inland tanks in Canada and then grow them in Panama.
 
Some activists are concerned that a decision on the salmon is imminent, but DeLancey said the agency is still reviewing comments from the industry and the public.
 
The FDA also has to decide whether to prepare a Finding of No Significant Impact or an Environmental Impact Statement, a preliminary decision that would be subject to a 30-day comment period.
 
The impact statement is based on an environmental analysis that Fish and Wildlife Service officials called inadequate, according to documents released to Truthout.
articles post